96 related articles for article (PubMed ID: 24342820)
21. Expression and prognostic significance of vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.
Li T; Zhu Y; Qin CY; Yang Z; Fang A; Xu S; Ren W
J Clin Pathol; 2012 Sep; 65(9):808-14. PubMed ID: 22734007
[TBL] [Abstract][Full Text] [Related]
22. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
[TBL] [Abstract][Full Text] [Related]
23. Tumor burden modeling versus progression-free survival for phase II decision making.
Kaiser LD
Clin Cancer Res; 2013 Jan; 19(2):314-9. PubMed ID: 23172885
[TBL] [Abstract][Full Text] [Related]
24. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
25. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
26. An adaptive biomarker basket design in phase II oncology trials.
Liu S; Takeda K; Rong A
Pharm Stat; 2023 Jan; 22(1):128-142. PubMed ID: 36163614
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
28. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
29. [Expression and clinical significance of metastasis-associated in colon cancer 1 (MACC1) in HBV-related hepatocellular carcinoma].
Chang XJ; Wang CP; Qu JH; Lu YY; Chen Y; Bai WL; Gao XD; Hao LY; Xu GL; Wang H; Yang YP
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):748-52. PubMed ID: 23291068
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
31. Evidence that naturopathic therapy including Cordyceps sinensis prolongs survival of patients with hepatocellular carcinoma.
Niwa Y; Matsuura H; Murakami M; Sato J; Hirai K; Sumi H
Integr Cancer Ther; 2013 Jan; 12(1):50-68. PubMed ID: 22544231
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of Romo1 promotes production of reactive oxygen species and invasiveness of hepatic tumor cells.
Chung JS; Park S; Park SH; Park ER; Cha PH; Kim BY; Chung YM; Woo SR; Han CJ; Kim SB; Suh KS; Jang JJ; Lee K; Choi DW; Lee S; Lee GY; Hahm KB; Shin JA; Kim BS; Noh KH; Kim TW; Lee KH; Yoo YD
Gastroenterology; 2012 Oct; 143(4):1084-94.e7. PubMed ID: 22749933
[TBL] [Abstract][Full Text] [Related]
33. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.
Levin VA; Ictech S; Hess KR
BMC Cancer; 2007 Jun; 7():106. PubMed ID: 17587447
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Lind PA; Naucler G; Holm A; Gubanski M; Svensson C
Acta Oncol; 2007; 46(2):230-3. PubMed ID: 17453374
[TBL] [Abstract][Full Text] [Related]
35. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
Shan M; Guo B; Liu H; Li Q; Zang Y
Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
[TBL] [Abstract][Full Text] [Related]
36. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
Chin Clin Oncol; 2014 Mar; 3(1):. PubMed ID: 25485277
[TBL] [Abstract][Full Text] [Related]
37. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
Su L; Chen X; Zhang J; Gao J; Yan F
Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
[TBL] [Abstract][Full Text] [Related]
38. Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints.
Uozumi R; Hamada C
J Biopharm Stat; 2017; 27(1):84-100. PubMed ID: 26881477
[TBL] [Abstract][Full Text] [Related]
39. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
Uozumi R; Yada S; Kawaguchi A
BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility estimation for assay cutoffs in early phase oncology enrichment trials.
Lunceford JK
Pharm Stat; 2015; 14(3):233-341. PubMed ID: 25846276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
